With a Vision of Making Quality Healthcare Affordable Through Drug Delivery Solutions Focusing On Patient Convenience and Adherence, ZIM’s value propositions is its ability to provide a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes for development, manufacture and supply of innovative and differentiated generic pharmaceutical products to its customers globally.
An overview of Zim Labs at a glance from its inception, current offerings to its path forward and the leadership behind the journey.
ZIM has filed 37 patents Registered over 170 formulations in various markets (mainly RoW).
Establishment of Company and
first manufacturing site.
WHO GMP Status and maiden
New Orally Disintegrating Strip (ODS)
Manufacturing Block Added.
WHO-GMP Status for Orally Disintegrating Strip Mfg. Facility.
Leading supplier of pharmaceutical
Developed Pellets, Granules and
Funding from private
Continued focus in core PFI
Over time ZIM has created a long term sustainable advantage by focused on Novel Drug Delivery Solutions (NDDS) segment through continuous innovation and development of non-infringing technology platforms and supply of high quality products at competitive prices.
ZIM leverages on its R&D capabilities and manufacturing skills to develop and supply differentiated generic products, in pre-formulation and formulation dosage forms, to business partners who need comprehensive support in product development, full manufacturing technical training, registration and sourcing of such differentiated products to boost their pipeline and compete.
ZIM supplies a wide range of solid dosage differentiated products across various therapeutic segments. ZIM is a pioneer in the OTF technology in India and focussed on growing this platform in partnership with marketing companies and product originators.
ZIM has a state of the art R&D centre with a team of over 90 professionals. ZIM is now setting up a new R&D centre with team, equipment and capabilities targeted for developed markets.
The Company is led by an experienced technocrat who is supported by a well-qualified professional management team.
ZIM has three manufacturing blocks (General, Cephalosporin and OTF). ZIM general block is EU-GMP and WHO-GMP approved. Its Cephalosporin and OTF blocks are WHO-GMP approved. ZIM is amongst the few companies in India to receive WHO-GMP approval for its OTF facility.
ZIM’s multi-pronged growth strategy comprises of:
• Developing new technology platforms & differentiated generic products for itself and under license arrangement.
• Manufacturing and supply of finished and semi-finished formulations for RoW as well as emerging markets.
• Development of the Thin Film as an alternate delivery platform across all markets.
The Company has improved its EBITDA Margins from 11% to 15% in last four years on account of continued focus on high margin businesses.
Our facilities are accredited with respected certifications from authorized independent bodies, which are generally accepted worldwide as a mark of approval of the quality of the manufacturer’s operational capabilities. These accreditations are: